Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Oramed Pharmaceuticals (ORMP) Debt to Equity (2016 - 2024)

Oramed Pharmaceuticals filings provide 11 years of Debt to Equity readings, the most recent being $0.19 for Q1 2024.

  • Quarterly Debt to Equity changed N/A to $0.19 in Q1 2024 from the year-ago period, while the trailing twelve-month figure was $0.19 through Mar 2024, changed N/A year-over-year, with the annual reading at $0.31 for FY2023, N/A changed from the prior year.
  • Debt to Equity hit $0.19 in Q1 2024 for Oramed Pharmaceuticals, down from $0.31 in the prior quarter.
  • Across five years, Debt to Equity topped out at $0.51 in Q3 2023 and bottomed at $0.0 in Q2 2021.
  • Average Debt to Equity over 4 years is $0.11, with a median of $0.0 recorded in 2020.
  • The largest annual shift saw Debt to Equity rose 23.17% in 2020 before it tumbled 41.91% in 2021.
  • Oramed Pharmaceuticals' Debt to Equity stood at $0.0 in 2020, then crashed by 74.17% to $0.0 in 2021, then skyrocketed by 36680.05% to $0.31 in 2023, then tumbled by 38.28% to $0.19 in 2024.
  • Per Business Quant, the three most recent readings for ORMP's Debt to Equity are $0.19 (Q1 2024), $0.31 (Q4 2023), and $0.51 (Q3 2023).